Mesalazine is safe for the treatment of IBD

D'Haens G; van Bodegraven A A
January 2004
Gut;Jan2004, Vol. 53 Issue 1, p155
Academic Journal
No abstract available.


Related Articles

  • Goals are symptom control, remission.  // New Zealand Doctor;2/10/2010, p23 

    The article presents information on the two ways to treat inflammatory bowel diseases (IBD), namely, remission induction and remission maintenance. Such treatments are said to be the result of the lack of cure for IBD. Several 5-aminosalicylate drugs can reportedly treat IBD including...

  • Allergy to topical corticosteroids in inflammatory bowel disease. Monk, B.E.; Skipper, D. // Gut;Apr2003, Vol. 52 Issue 4, p597 

    Describes a case of allergy to topical corticosteroids in a patient with inflammatory bowel disease. Clinical pathology; Failure of the IBD to respond to appropriate topical steroid therapy; Treatment with oral Asacol (mesalazine).

  • Mesalazine-Induced Multi-Organ Hypersensitivity. Sposato, Bruno; Allegri, Maria Pia; Riccardi, Maria Piera; Chigiotti, Silvia; Nencioni, Cesira; Ricciardi, Barbara; Carli, Tiziana; Cresti, Alberto; Perari, Maria Grazia; Migliorini, Maria Giovanna; Toti, Mario // Clinical Drug Investigation;2010, Vol. 30 Issue 6, p413 

    Mesalazine therapy for ulcerative colitis has been reported to be effective and safe. Rare cases of mesalazine-induced renal, pancreatic, myo-pericardial, pleuro-pulmonary and haematological toxicity have been described separately. We report a case characterized by the simultaneous presence of...

  • Inflammatory Bowel Disease: Back to the Future. Sachar, David B. // American Journal of Gastroenterology;Apr1990, Vol. 85 Issue 4, p373 

    Discusses medicinal treatments and experimental models associated with inflammatory bowel disease (IBD). Techniques used in preparing mesalamine and mesalazine; Basis of the anti-inflammatory actions of hydrocortisone; Efficacy of azathioprine and 6-mercaptopurine; Reaction if IBD epithelial...

  • Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis. Eun Hye Park; Byung Jin Kim; Jung Kwon Huh; Eun Haeng Jeong; Sang Hyuk Lee; Ki Bae Bang; Ji Soo Seol; Joo Wook Sung; Bum Soo Kim; Jin Ho Kang // Journal of Cardiovascular Ultrasound;Sep2012, Vol. 20 Issue 3, p154 

    Inflammatory bowel disease (IBD) is considered as a dysregulated immune mediated disease. Pericarditis in IBD is a very rare disease both as an extra-intestinal manifestation of IBD and an adverse reaction of therapeutic drug for IBD such as mesalazine or sulfasalazine. A 26-year-old IBD male...

  • The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Klotz, U. // European Journal of Clinical Pharmacology;Aug2000, Vol. 56 Issue 5, p353 

    Objective: To discuss the pharmacological properties of aminosalicylates and their potential value in the treatment of chronic inflammatory bowel disease (IBD). Methods: A review of clinical studies on the pharmacokinetics and mode of action of aminosalicylates is provided. In addition, the...

  • Efficacy of subcutaneous immunoglobulins in primary immunodeficiency with Crohn's-like phenotype: report of a case. SANGES, M.; SPADARO, G.; MINIERO, M.; MATTERA, D.; SOLLAZZO, R.; D'ARMIENTO, F. P.; DE PALMA, G. D.; PECORARO, A.; BORRELLI, F.; GENOVESE, A.; D'ARIENZO, A. // European Review for Medical & Pharmacological Sciences;Jul2015, Vol. 19 Issue 14, p2641 

    Common variable immune deficiency (CVID) is the most frequent primary immunodeficiency in adults. In CVID, the prevalence of gastrointestinal manifestations ranges between 2 and 50% with a complication-related morbidity second only to that of the respiratory tract. In some cases, clinical and...

  • Molecular Targets of Mesalazine in Colorectal Cancer. Stolfi, Carmine; Pellegrini, Roberto; Pallone, Francesco; Monteleone, Giovanni // Current Cancer Therapy Reviews;2008, Vol. 4 Issue 4, p262 

    Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent...

  • Inflammatory Bowel Disease: Its Present and Its Future. Kirsner, Joseph B. // American Journal of Gastroenterology;Nov1989, Vol. 84 Issue 11, p1358 

    Discusses the developments in the treatment of inflammatory bowel disease (IBD) as of 2005. Experiment done to determine the treatment for IBD; Pathogenesis of IBD; Microbial cause of IBD.

  • Azathioprine/ciclosporin/mesalazine.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p32 

    The article presents case studies of eight patients who developed various toxicities while receiving ciclosporin, azathioprine or mesalazine for inflammatory bowel diseases (IBD), and one patient died.


Read the Article


Sign out of this library

Other Topics